Drug release and skin penetration from solid lipid nanoparticles and a base cream: A systematic approach from a comparison of three glucocorticoids

Skin Pharmacology and Physiology

Volumn 24, Issue 4, 2011, Pages 199-209

  Schlupp, P ^a,b   Blaschke, T ^a   Kramer, K D ^a   Holtje H D ^c   Mehnert, W ^a   Schafer Korting M ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Drug release; Epidermal targeting; Glucocorticoids; Skin penetration; Solid lipid nanoparticles

Indexed keywords

BETAMETHASONE VALERATE; GLYCEROL BEHENATE; POLOXAMER; PREDNICARBATE; PREDNISOLONE; SOLID LIPID NANOPARTICLE; WATER OIL CREAM;

ADULT; AGED; ARTICLE; CREAM; DRUG PENETRATION; DRUG RELEASE; FEMALE; HUMAN; HUMAN TISSUE; NANOPHARMACEUTICS; PRIORITY JOURNAL; SKIN PENETRATION;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AGED; BETAMETHASONE 17-VALERATE; FEMALE; GLUCOCORTICOIDS; HUMANS; LIPIDS; MIDDLE AGED; NANOPARTICLES; OINTMENT BASES; PARTICLE SIZE; PREDNISOLONE; SKIN; SKIN ABSORPTION; YOUNG ADULT;

EID: 79951854727     PISSN: 16605527     EISSN: 16605535     Source Type: Journal    
DOI: 10.1159/000324053     Document Type: Article

References (61)

1. Bouwstra JA, Honeywell-Nguyen PL, Gooris GS, Ponec M: Structure of the skin barrier and its modulation by vesicular formulations. Prog Lipid Res 2003;42:1-36. (Pubitemid 35418207)
2. Joshi MD, Müller RH: Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm 2009;71:161-172.
3. Wissing SA, Kayser O, Müller RH: Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 2004;56:1257-1272. (Pubitemid 38510473)
4. Müller RH, Runge S, Ravelli V, Mehnert W, Thünemann AF, Souto EB: Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals. Int J Pharm 2006;317:82-89. (Pubitemid 43866342)
5. Yang S, Zhu J, Lu Y, Liang B, Yang C: Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res 1999;16:751-757. (Pubitemid 29227107)
6. Pardeike J, Hommoss A, Müller RH: Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm 2009;366:170-184.
7. Schäfer-Korting M, Mehnert W, Korting HC: Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv Drug Deliv Rev 2007;59:427-443. (Pubitemid 47259224)
8. Goebel A, Neubert RHH: Dermal peptide delivery using colloidal carrier systems. Skin Pharmacol Physiol 2008;21:3-9.
9. Santos P, Watkinson AC, Hadgraft J, Lane ME: Application of microemulsions in dermal and transdermal drug delivery. Skin Pharmacol Physiol 2008;21:246-259.
10. Mehnert W, Mäder K: Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 2001;47:165-196. (Pubitemid 32324113)
11. Küchler S, Herrmann W, Panek-Minkin G, Blaschke T, Zoschke C, Kramer KD, Bittl R, Schäfer-Korting M: SLN for topical application in skin diseases - characterization of drug-carrier and carrier-target interactions. Int J Pharm 2010;390:225-233.
12. Küchler S, Radowski MR, Blaschke T, Dathe M, Plendl J, Haag R, Schäfer-Korting M, Kramer KD: Nanoparticles for skin penetration enhancement - a comparison of a dendritic core-multishell-nanotransporter and solid lipid nanoparticles. Eur J Pharm Biopharm 2009;71:243-250.
13. Kuntsche J, Bunjes H, Fahr A, Pappinen S, Ronkko S, Suhonen M, Urtti A: Interaction of lipid nanoparticles with human epidermis and an organotypic cell culture model. Int J Pharm 2008;354:180-195. (Pubitemid 351400323)
14. Lombardi Borgia S, Regehly M, Sivaramakrishnan R, Mehnert W, Korting HC, Danker K, Röder B, Kramer KD, Schäfer-Korting M: Lipid nanoparticles for skin penetration enhancement - correlation to drug localization within the particle matrix as determined by fluorescence and parelectric spectroscopy. J Control Release 2005;110:151-163. (Pubitemid 41713939)
15. Stecova J, Mehnert W, Blaschke T, Kleuser B, Sivaramakrishnan R, Zouboulis CC, Seltmann H, Korting HC, Kramer KD, Schäfer-Korting M: Cyproterone acetate loading to lipid nanoparticles for topical acne treatment: particle characterisation and skin upta ke. Pharm Res 2007;24:991-1000. (Pubitemid 46675401)
16. Braem C, Blaschke T, Panek-Minkin G, Herrmann W, Schlupp P, Paepenmüller T, Müller-Goyman C, Mehnert W, Bittl R, Schäfer-Korting M, Kramer KD: Interaction of drug molecules with carrier systems as studied by parelectric spectroscopy and electron spin resonance. J Control Release 2007;119:128-135. (Pubitemid 46561548)
17. Jores K, Haberland A, Wartewig S, Mäder K, Mehnert W: Solid lipid nanoparticles (SLN) and oil-loaded SLN studied by spectrofluorometry and Raman spectroscopy. Pharm Res 2005;22:1887-1897. (Pubitemid 41504342)
18. Santos Maia C, Mehnert W, Schaller M, Korting HC, Gysler A, Haberland A, Schäfer-Korting M: Drug targeting by solid lipid nanoparticles for dermal use. J Drug Target 2002;10:489-495. (Pubitemid 35230199)
19. Sivaramakrishnan R, Nakamura C, Mehnert W, Korting HC, Kramer KD, Schäfer-Korting M: Glucocorticoid entrapment into lipid carriers - characterisation by parelectric spectroscopy and influence on dermal upta ke. J Control Release 2004;97:493-502. (Pubitemid 38802951)
20. Mitriaikina S, Müller-Goymann CC: Comparative permeation studies of nondiluted and diluted betamethasone-17-valerate semisolid formulations through isolated human stratum corneum and artificial skin construct. Skin Pharmacol Physiol 2009;22:142-150.
21. Zur Mühlen A, Mehnert W: Drug release and release mechanism of prednisolone loaded solid lipid nanoparticles. Pharmazie 1998;53:552-555. (Pubitemid 28376685)
22. Rawle A: Basic principles of particle size analysis. Technical paper. Malvern Instruments Ltd, Worcestershire, UK 2001.
23. Siek mann B, Westesen K: T hermoa nalysis of the recrystallization process of melt-homogenized glyceride nanoparticles. Colloid Surf B Biointerfaces 1994;3:159-175.
24. Blaschke T, Kankate L, Kramer KD: Structure and dynamics of drug-carrier systems as studied by parelectric spectroscopy. Adv Drug Deliv Rev 2007;59:403-410. (Pubitemid 47259222)
25. CDER: Guidance for industry: nonsterile semisolid dosage forms. 1997.
26. Shah VP, Elkins J, Lam S-Y, Skelly JP: Determination of in vitro drug release from hydrocortisone creams. Int J Pharm 1989;53:53-59. (Pubitemid 19160339)
27. Higuchi T: Rate of release of medicaments from ointment bases containing drugs in suspension. J Pharm Sci 1961;50:874-875.
28. Lombardi Borgia S, Schlupp P, Mehnert W, Schäfer-Korting M: In vitro skin absorption and drug release - a comparison of six commercial prednicarbate preparations for topical use. Eur J Pharm Biopharm 2008;68:380-389.
29. Niedorf F, Schmidt E, Kietzmann M: The automated, accurate and reproducible determination of steady-state permeation parameters from percutaneous permeation data. Altern Lab Anim 2008;36:201-213. (Pubitemid 351861003)
30. OECD: OECD guidelines for the testing of chemicals. No 428: Skin absorption: in vitro method. 2004.
31. Schäfer-Korting M, Bock U, Diembeck W, Düsing HJ, Gamer A, Haltner-Ukomadu E, Hoffmann C, Kaca M, Kamp H, Kersen S, Kietzmann M, Korting HC, Krächter HU, Lehr CM, Liebsch M, Mehling A, Müller-Goymann C, Netzlaff F, Niedorf F, Rübbelke MK, Schäfer U, Schmidt E, Schreiber S, Spielmann H, Vuia A, Weimer M: The use of reconstructed human epidermis for skin absorption testing: results of the validation study. Altern Lab Anim 2008;36:161-187. (Pubitemid 351861001)
32. Gysler A, Lange K, Korting HC, Schäfer-Korting M: Prednicarbate biotransformation in human foreskin keratinocytes and fibroblasts. Pharm Res 1997;14:793-797. (Pubitemid 27281676)
33. Kubota K, Ademola J, Maibach HI: Simultaneous diffusion and metabolism of betamethasone 17-valerate in the living skin equivalent. J Pharm Sci 1995;84:1478-1481.
34. Gysler A, Kleuser B, Sippl W, Lange K, Korting HC, Höltje HD, Korting HC, Schäfer-Korting M: Skin penetration and metabolism of topical glucocorticoids in reconstructed epidermis and in excised human skin. Pharm Res 1999;16:1386-1391. (Pubitemid 29449375)
35. Kubota K, Ademola J, Maibach HI: Metabolism and degradation of betamethasone 17-valerate in homogenized living skin equivalent. Dermatology 1994;188:13-17. (Pubitemid 24009105)
36. Ryatt KS, Feather JW, Mehta A, Dawson JB, Cotterill JA, Swallow R: The stability and blanching efficacy of betamethasone-17-valerate in emulsifying ointment. Br J Dermatol 1982;107:71-76. (Pubitemid 12085077)
37. El Maghraby GM, Williams AC, Barry BW: Drug interaction and location in liposomes: correlation with polar surface areas. Int J Pharm 2005;292:179-185. (Pubitemid 40255799)
38. Ertl P, Rohde B, Selzer P: Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem 2000;43:3714-3717.
39. Potts RO, Guy RH: Predicting skin permeability. Pharm Res 1992;9:663-669.
40. Souto EB, Müller RH: Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes; in Schäfer-Korting M (ed): Handbook of Experimental Pharmacology. Berlin, Springer, 2009, vol 197: Drug delivery, pp 115-141.
41. Schubert MA, Schicke BC, Müller-Goymann CC: Thermal analysis of the crystallization and melting behavior of lipid matrices and lipid nanoparticles containing high amounts of lecithin. Int J Pharm 2005;298:242-254. (Pubitemid 40828345)
42. Guttman DE, Meister PD: The kinetics of the base-catalyzed degradation of prednisolone. J Am Pharm Assoc (Baltim) 1958;47:773-778.
43. Oesterling TO, Guttman DE: Factors influencing stability of prednisolone in aqueous solution. J Pharm Sci 1964;53:1189-1192.
44. Guy RH, Hadgraft J: On the determination of drug release rates from topical dosage forms. Int J Pharm 1990;60: R1-R3. (Pubitemid 20171030)
45. Higuchi WI: Analysis of data on the medicament release from ointments. J Pharm Sci 1962;51:802-804.
46. Higuchi T: Physical chemical analysis of percutaneous absorption process from creams and ointments. J Soc Cosmet Chem 1960;11:85-97.
47. Zur Mühlen A, Schwarz C, Mehnert W: Solid lipid nanoparticles (SLN) for controlled drug delivery - drug release and release mechanism. Eur J Pharm Biopharm 1998;45:149-155. (Pubitemid 28167741)
48. Spireas S, Sadu S: Enhancement of prednisolone dissolution properties using liquisolid compacts. Int J Pharm 1998;166:177-188. (Pubitemid 28255225)
49. Ibekwe VC, Fadda HM, Parsons GE, Basit AW: A comparative in vitro assessment of the drug release performance of pH-responsive polymers for ileo-colonic delivery. Int J Pharm 2006;308:52-60. (Pubitemid 43097235)
50. Müller RH, Mäder K, Gohla S: Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 2000;50:161-177. (Pubitemid 30326695)
51. Wirén K, Frithiof H, Sjoqvist C, Loden M: Enhancement of bioavailability by lowering of fat content in topical formulations. Br J Dermatol 2009;160:552-556.
52. Moss GP, Dearden JC, Patel H, Cronin MT: Quantitative structure-permeability relationships (QSPRS) for percutaneous absorption. Toxicol In Vitro 2002;16:299-317. (Pubitemid 34521704)
53. Hewitt PG, Perkins J, Hotchkiss SA: Metabolism of fluroxypyr, fluroxypyr methyl ester, and the herbicide fluroxypyr methylheptyl ester. I. During percutaneous absorption through fresh rat and human skin in vitro. Drug Metab Dispos 2000;28:748-754. (Pubitemid 30470823)
54. Cevc G: Lipid vesicles and other colloids as drug carriers on the skin. Adv Drug Deliv Rev 2004;56:675-711. (Pubitemid 38326939)
55. Cosco D, Celia C, Cilurzo F, Trapasso E, Paolino D: Colloidal carriers for the enhanced delivery through the skin. Expert Opin Drug Deliv 2008;5:737-755.
56. Date AA, Patravale VB: Microemulsions: applications in transdermal and dermal delivery. Crit Rev Ther Drug Carrier Syst 2007;24:547-596. (Pubitemid 351234919)
57. Guillard EC, Laugel C, Baillet-Guffroy A: Molecular interactions of penetration enhancers within ceramides organization: a FTIR approach. Eur J Pharm Sci 2009;36:192-199.
58. Blaschke T, Spangenberg T, Schlupp P, Dathe M, Szcymczak W, Mehnert W, Korting HC, Thalhammer S, Niehus H, Schäfer-Korting M, Kramer KD: Interaction of drug-carrier systems with targets - a study using atomic force microscopy. Pharmazie 2010;65:657-664.
59. 2 and ZnO nanoparticle percutaneous absorption. Skin Pharmacol Physiol 2009;22:266-275.
60. Nohynek GJ, Dufour EK, Roberts MS: Nanotechnology, cosmetics and the skin: is there a health risk? Skin Pharm Phys 2008;21:136-149. (Pubitemid 351793742)
61. Zhang LW, Monteiro-Riviere NA: Assessment of quantum dot penetration into intact, tape-stripped, abraded and flexed rat skin. Skin Pharmacol Physiol 2008;21:166-180. (Pubitemid 351793745)